Pharmacokinetics of Oral Calcium Carbonate in Parturients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jessica R Ansari, MD, MS
- Phone Number: 650-723-4000
- Email: jansari@stanford.edu
Study Contact Backup
- Name: Jordan Abrams, MD
- Phone Number: 650-723-4000
- Email: abramsj@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford Children's Health, Lucile Packard Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pregnant female subjects at the study institution, admitted for labor (spontaneous, augmented, or induced)
Exclusion Criteria:
- severe range blood pressure (BP >160/>110) within the 48 hours prior to delivery
- patient age <18 years or >45 years
- renal dysfunction with a documented serum Cr > 1.0 mg/dL
- known history of congenital or acquired cardiac disease or history of arrhythmia
- patient taking digoxin
- patient currently taking a calcium channel blocker
- Weight <55kg or >100kg, or
- receiving magnesium infusion within 24 hours prior to or during cesarean delivery
- Prior or planned administration of calcium by the obstetric or anesthesiology teams for clinical indications within 24 hours of study enrollment
- Patient took a calcium supplement in the past 48 hours
- Patient status is NPO (nothing by mouth) as ordered by the clinical team
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Oral calcium carbonate
Patients take a single dose of oral calcium carbonate 1200mg
|
Participants receive a single, open-label dose of oral calcium carbonate 1200mg
|
|
Experimental: Oral calcium citrate
Participants receive a single oral dose of calcium citrate 1250mg
|
Participants receive a single oral dose of calcium citrate 1250mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ionized calcium concentration
Time Frame: 4 hours
|
Ionized calcium (mmol/L) is measured at baseline and over 5 additional convenience timepoints over the 4 hours after ingestion of calcium carbonate 3000mg.
|
4 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jessica Ansari, MD, MS, Stanford University
Publications and helpful links
General Publications
- Ansari JR, Kalariya N, Carvalho B, Flood P, Guo N, Riley E. Calcium chloride for the prevention of uterine atony during cesarean delivery: A pilot randomized controlled trial and pharmacokinetic study. J Clin Anesth. 2022 Sep;80:110796. doi: 10.1016/j.jclinane.2022.110796. Epub 2022 Apr 18.
- Ansari JR, Yarmosh A, Michel G, Lyell D, Hedlin H, Cornfield DN, Carvalho B, Bateman BT. Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol. 2024 Jan 1;143(1):104-112. doi: 10.1097/AOG.0000000000005441. Epub 2023 Nov 3.
- Ansari J, Carvalho B, Shafer SL, Flood P. Pharmacokinetics and Pharmacodynamics of Drugs Commonly Used in Pregnancy and Parturition. Anesth Analg. 2016 Mar;122(3):786-804. doi: 10.1213/ANE.0000000000001143.
- Ansari JR, Conti DJ, Michel G, Yarmosh A, Cole NM, Shafer SL. Bioequivalence and Pharmacokinetics of Intravenous Calcium during Cesarean Delivery. Anesthesiology. 2025 Jan 1;142(1):121-131. doi: 10.1097/ALN.0000000000005248.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Female Urogenital Diseases and Pregnancy Complications
- Obstetric Labor Complications
- Pregnancy Complications
- Hemorrhage
- Puerperal Disorders
- Uterine Hemorrhage
- Pathological Conditions, Signs and Symptoms
- Postpartum Hemorrhage
- Organic Chemicals
- Acids, Acyclic
- Carboxylic Acids
- Inorganic Chemicals
- Minerals
- Calcium Compounds
- Carbon Compounds, Inorganic
- Citrates
- Tricarboxylic Acids
- Carbonates
- Carbonic Acid
- Citric Acid
- Calcium Carbonate
- Calcium Citrate
Other Study ID Numbers
Other Study ID Numbers
- 77182
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.